Patent ID: 7098217

Claim:
A method of treating a subject afflicted with a disorder characterized by over expression of corticotropin releasing factor (CRF), which method comprises administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt form thereof, wherein: R 1 is selected from the group consisting of HC 1-4 alkyl, CN, and CF 3 ; alternatively R 1 is —OR 1a , wherein R 1a is C 1 –C 4 alkyl; R 2 is selected from the group consisting of C 1 –C 6 alkyl and C 3 –C 7 cycloalkyl; R 3 is selected from the group consisting of aryl and heteroaryl; R 4 is selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 3-8 cycloalkyl and benzyl; R 4 is optionally substituted with 0–1 1-naphthalenyl groups; alternatively R 4 is optionally substituted with 0–3 substituents independently selected at each occurrence from the group consisting of aryl, C 1-6 alkyl, C 2-8 alkenyl, —OR 10 , —NR 10 R 12 , CF 3 , C 1-4 alkoxy-C 1-4 alkyl and C 3-8 cycloalkyl; R 10 is selected from the group consisting of H and benzyl; R 12 is selected from the group consisting of H, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy-C 1-4 alkyl, C 3-6 cycloalkyl and C 3-6 cycloalkyl-C 1-6 alkyl; R 13 is selected from the group consisting of C 1-6 alkyl and C 1-4 haloalkyl; aryl is phenyl optionally substituted with 0–5 substituents independently selected at each occurrence from the group consisting of phenyl, C 1-6 alkyl, —OR 13 , Br, Cl, F, I and C 1-4 haloalkyl; and heteroaryl is pyridyl optionally substituted with 0–4 substituents independently selected at each occurrence from the group consisting of C 1-6 alkyl and —OR 13 .